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Repression of transcription by the full-length E2 protein of papillomaviruses (PV) seems to occur when the E2 binding sites
and those of positively acting cellular factors overlap. Previously, we showed that RUNX1 (formerly called CBF) binds to the
repression-mediating E2 binding site P2 of human PV type 8 (HPV8). By a yeast one-hybrid system we could identify an
unknown protein binding also to P2, tentatively called PBF (papillomavirus binding factor). PBF recognizes the sequence
CCGG, which represents the 3 half of the E2 binding site just adjacent to the RUNX1 motif. PBF also binds to the
repression-mediating E2 BS-1 in BPV1, which is conserved to P2 of HPV8. Point mutations destroying PBF binding to HPV8
P2 and BPV-1 E2 BS-1 in vitro reduce promoter activity in corresponding reporter constructs. Our results suggest that PBFINTRODUCTION
Human papillomaviruses (HPVs) induce benign epi-
thelial tumors of the skin or the mucosa. Infections with
certain HPV types have a high risk of progressing to
carcinomas (zur Hausen, 1996). HPV5 and HPV8, which
both infect the skin and belong to the group of viruses
associated with the rare disease epidermodysplasia ver-
ruciformis (ev), are present in 90% of the squamous cell
carcinomas which often develop in these patients (Pfis-
ter, 1992). In skin cancers of non-ev patients HPV DNA
can also be found; however, the role HPVs play in the
malignant progression is not clear (Pfister and ter Scheg-
get, 1997). A tissue-specific enhancer present in the long
control region (LCR) or noncoding region (NCR) seems to
determine the epithelial cell tropism of PVs. The activity
of this enhancer is tightly controlled by a complex inter-
play between ubiquitous and keratinocyte-specific tran-
scription factors binding to their recognition sites
present mostly within the LCR. The exact constellation of
protein recognition motifs differs between individual HPV
types. However, the presence of AP1, NF1, and YY1
binding sites seems to be a consistent and functionally
important feature of constitutive enhancer elements of
HPVs, since also in skin-specific HPV types these factors
have been demonstrated to be involved in regulation of
promoter activity (reviewed in Fuchs and Pfister, 1997).
The participation of as yet uncharacterized cellular tran-
scription factors is suggested by findings that mutations
1103outside of known factor binding sites still reduce pro-
moter activity (Horn et al., 1993; Stubenrauch and Pfister,
1994; Demeret et al., 1997).
In addition to cellular factors, viral gene expression is
modulated by the viral E2 protein, which is also required
for viral DNA replication (McBride et al., 1991). E2 regu-
lates transcription through binding as a dimer to its
specific recognition sequence ACCN6GGT, which occurs
several times in PV genomes (Dostatni et al., 1988;
McBride et al., 1989). The full-length E2 protein can either
be an activator or a repressor of viral transcription. Ac-
tivation requires the N-terminal activation domain con-
tacting cellular targets like the transcription factors TBP,
TFIIB, Sp1, AMF1, and CBP/p300 (Li et al., 1991; Spalholz
et al., 1991; Rank and Lambert, 1995; Steger et al., 1995;
Benson et al., 1997; Breiding et al., 1997; Yao et al., 1998;
Lee et al., 2000; Peng et al., 2000). Repression of PV gene
expression by the full-length E2 protein usually occurs by
binding to promoter proximal E2 binding sites, which
overlap with binding sites for cellular transcription fac-
tors necessary for promoter activity, as demonstrated for
different PV types. Thus, promoter repression might re-
sult from displacement of these cellular factors by E2.
Repression of viral gene expression by E2 has been
demonstrated in HPV8. The promoter in position 7535
(P7535) is activated by small amounts of E2 and a repres-
sion of promoter activity is observed at large amounts.
The activation is due to binding to high-affinity binding
sites, whereas repression is mediated by the low-affinity
binding site P2 located close to the TATA box of the P7535.might play a role in transcription of PV genes and in E2-m
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in the absence of E2, suggesting that cellular factors
required for basal promoter activity might bind here
(Stubenrauch and Pfister, 1994; Stubenrauch et al., 1996).
We showed previously that the mouse polyoma en-
hancer binding protein 2 (PEBP2), a homologue of the
human core binding factor (CBF, also called AML1),
which is now called RUNX1 according to the recently
revised nomenclature, binds to the 5 half of this E2
binding site and E2 competes with RUNX1 for DNA
binding (Schmidt et al., 1997).
RUNX1 was also found to play a role in promoter
activity and E2-mediated repression in BPV4 and BPV1
(Jackson and Campo, 1995; Schmidt et al., 1997). In BPV1,
which contains 17 E2 binding sites, the full-length E2
was shown to strongly activate transcription of several
BPV1 promoters (Spalholz et al., 1987, 1991), but to re-
press one promoter at position 7185 by binding to the
low-affinity E2 binding site 1 (BS-1), located just down-
stream of the promoter (Li et al., 1989; Stenlund and
Botchan, 1990; Vande Pol and Howley, 1990). The se-
quences around the repression-mediating E2 binding
sites BS-1 of BPV1 and P2 of HPV8 are highly conserved
and we could demonstrate that RUNX1 also binds the
BS-1 of BPV1. Mutations that eliminate binding of RUNX1
in vitro reduce the activity of P7185 reporter constructs and
largely abolish repression by E2. These results suggest
that repression of HPV8 P7535 and BPV 1 P7185 by E2 is
mediated by competition for DNA binding between E2
and RUNX1 (Schmidt et al., 1997).
Since a mutation within P2, which does not abolish
binding of RUNX1 in vitro reduces P7535 activity in reporter
constructs (Stubenrauch and Pfister, 1994; Stubenrauch
et al., 1996; Schmidt et al., 1997), an additional cellular
factor might bind to this E2 binding site and be displaced
by E2. Here, we report the cloning of the gene for a novel
cellular protein with the help of the yeast one-hybrid
system by its ability to bind to HPV8 P2 and the charac-
terization of its role in regulation of PV gene expression.
RESULTS
Mutations within the HPV8 E2 binding site P2 reduce
the activity of the P7535 promoter
The promoter at position 7535 (P7535) appears to be the
late promoter of HPV8. Its relative activity is 20-fold
higher than that of the promoter at position 175, which is
most likely responsible for the expression of the early
genes (Stubenrauch et al., 1992). Previously, we showed
that RUNX1 is binding to the 5 half of the E2 binding site
P2 of HPV 8 in vitro and that an intact RUNX1 binding site
is required for full activity of the P7535. However, a muta-
tion within P2 which did not affect the binding of RUNX1
in vitro (Schmidt et al., 1997) also significantly reduced
promoter activity (Stubenrauch et al., 1996), suggesting
that an additional cellular factor might bind within this E2
binding site adjacent to RUNX1. To further characterize
the binding site of this putative cellular factor, we intro-
duced additional point mutations adjacent to the RUNX1
binding site into the background of the reporter plasmid
HPV8 p7535-Luc, containing part of the NCR of HPV8 in
front of the luciferase gene. The HPV8 segment includes
the E2 binding sites P1 and P2 and P7535 (Fig. 1). The early
promoter is not present in this reporter construct. Tran-
siently transfecting these constructs into C33A cells re-
vealed that in addition to the previously observed ex-
FIG. 1. Mutations within the HPV8 E2 binding site P2 reduce P7535
activity. Schematic representation of the reporter construct HPV8
p7535-Luc containing part of the NCR of HPV8 including the promoter
P7535 in front of the luciferase gene. The TATA box of P7535 and the
RUNX1 binding site are indicated. Point mutations within P2 in corre-
sponding reporter constructs pP2C-Luc, pP2D-Luc, pP2E-Luc,
pmtRUNX1-Luc, and pP2D/mtRUNX1-Luc are shown beneath. C33A
and RTS3b cells were transiently transfected with 2 g of reporter
construct as indicated. In RTS3b cells, the P7535-Luc construct, contain-
ing the wildtype P7535 promoter, revealed a 20-fold higher relative light
unit (RLU) value compared to the construct containing the luciferase
gene under control of the minimal adenovirus major late core promoter
(see Fig. 6). To account for variations in transfection efficiencies, RLUs
have been divided by the -Gal activity, an expression vector for which
has been cotransfected in each case. The resulting relative activity of
the wildtype was set as 100% and the percentage activity of the mutants
was determined. The values represent the average of 10 independent
experiments. The standard deviations represent the variations of the
percentage activities obtained by the mutants compared to the wild-
type.
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change of the CC to AA within the central nucleotides of
P2 present in the reporter construct pP2C-Luc (Stuben-
rauch et al., 1996) mutations of the neighboring CG (Fig.
1, construct pP2D-Luc) also reduced the activity of the
P7535 by about 40%. The mutations of the TA to CG at the
3 end of the E2 binding site (Fig. 1, construct pP2E-Luc)
did not significantly reduce promoter activity. The effects
of the point mutations were similar in the human skin
keratinocyte cell line RTS3b (Purdie et al., 1993) (Fig. 1).
These results support the notion that a binding site for a
cellular factor required for the activity of the P7535 is
located in the 3 half of the E2 binding site P2.
To analyze the role of both factors binding here, we
introduced point mutations abolishing the binding of
RUNX1 in vitro (Schmidt et al., 1997) into the background
of pP2D Luc. In C33A cells, mutations within the RUNX1
motif did not further reduce the activity observed with
pP2D-Luc (Fig. 1, construct pP2D/mtRUNX1-Luc),
whereas in RTS3b cells the promoter retained only 35%
of its activity when both binding sites were mutated.
Mutations abolishing RUNX1 binding alone also had a
stronger effect in RTS3b cells. Promoter activity was
reduced by about 20% in C33A cells and by 40% in RTS3b
cells. The minor role of RUNX1 in C33A cells could
previously be correlated with a reduced concentration of
endogenous RUNX1 in C33A cells compared to RTS3b
cells (Schmidt et al., 1997).
Cloning of the gene for a novel factor, PBF, binding to
HPV8 P2
To identify this unknown factor we used the yeast
one-hybrid system, allowing systematic screening of a
cDNA library. Four copies of the HPV8 P2 element were
cloned into the vector pHISi-1 (Clontech) upstream of the
PHis promoter of yeast, controlling the expression of the
histidine gene. In addition, five copies of the same oli-
gonucleotide were cloned into the vector pLacZi, up-
stream of the Pcyc, directing the expression of the -gal
gene. Both constructs were integrated into the genome
of the yeast strain YM4271. The resulting yeast strain was
transformed with a cDNA expression library of the hu-
man keratinocyte cell line HaCat, fused to the Gal4
activation domain (AD) (purchased from Clontech, Palo
Alto, CA). A total of 4.5  106 independent clones were
plated onto agar plates with selective medium and the
inhibitor of the HIS3 gene product 3-AT. Out of 90 colo-
nies, well grown in the presence of 75 mM 3-AT, 11
showed increased -gal activity, indicating that in addi-
tion to the PHis the Pcyc was also activated by the fusion
protein composed of the cDNA part and the Gal4 AD
expressed in these clones. Sequencing of these cDNA
encoding plasmids revealed that 6 cDNAs encoded the
same ORF, with three different types of clones differing in
the respective 5 ends. The ORF encodes an as yet
unknown protein. Screening dbEST (Expressed Se-
quence Tag database) (Adams et al., 1995) showed that
the cDNAs isolated here are identical to cDNAs which
have been found in a variety of different cell lines and
tissues, like HeLa cells, Jurkat T-cells, and testis and
lung carcinoma cells from Homo sapiens (data not
shown). The longest insert we could isolate had a size of
1400 bp. The 3 end revealed a stop codon, demonstrat-
ing that our clone has its entire 3 end. Since no in-frame
stop codon was detected at the 5 end we performed 5
RACE (rapid amplification of cDNA ends) using RNA from
HaCat cells in order to clone additional 5 sequences.
We isolated two types of clones: the first contained an
additional 342 bases, with an in-frame ATG at the 5 end;
the second type of clone had a further 336 bases beyond
this ATG with several in-frame stop codons, suggesting
that all clones contain the 5 end of the gene. The
sequence of the full-length gene, which encodes a pro-
tein composed of 513 amino acids, is depicted in Fig. 2.
Further analysis of the amino acid sequence revealed
the presence of a putative zinc finger. Pairs of histidines
and cysteines are spaced by 12 amino acids; thus the
zinc finger conforms to the classical zinc finger of the
TFIIIA type. Overall, the protein is rich in proline, alanine,
and serine, with contents of about 11% each. The gene is
located on chromosome 8, consists of 10 exons, and
spans 36 kb.
To analyze the cellular distribution of the protein en-
coded by this cDNA, which we tentatively called PBF
(papillomavirus binding factor), we generated antibodies
against recombinant (r)PBF. Therefore, the reconstituted
ORF encoding PBF was cloned into the bacterial expres-
sion vector pET14B (Novagene), which allows the ex-
pression of the protein in bacteria with a tag of six
histidines(His) at its N-terminus. After induction of ex-
pression, a novel protein with a molecular mass of about
70 kDa was detected, which could be purified on nickel–
agarose. As shown in the Western blot in Fig. 2B, the
antiserum generated against this protein recognized two
proteins of about 70 kDa in nuclear extracts from RTS3b
cells, which have been transiently transfected with a
eukaryotic expression vector for PBF. The two bands
could also be detected in nontransfected cells, although
they were weak. The smaller of the two proteins migrates
slightly faster than bacterially expressed purified His-
PBF. The second protein revealed a slightly slower mi-
gration and might be a modified version of PBF. In cor-
relation with this, the sequence of PBF reveals a series
of phosphorylation sites. Nuclear localization of PBF was
also confirmed by indirect immunofluorescence tests of
C33A and RTS3b cells transiently transfected with the
expression vector for PBF. Again, also in nontransfected
cells, weak nuclear fluorescence could be observed (Fig.
2B) which was not present when the preimmune serum
was used (data not shown).
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PBF recognizes the CCGG motif within the 3 half of
HPV8 P2
To analyze DNA binding of PBF, purified full-length PBF
(His-PBF) as well as the C-terminal 399 amino acids,
which are encoded by the cDNA insert, originally identi-
fied by the one-hybrid system (His-NPBF), was used in
gel-shift assays, as indicated in the figures. It could be
confirmed that PBF is able to bind to the P2 element of
HPV8. The specificity of the binding was demonstrated
by heterologous and homologous competition (Fig. 3A).
An oligonucleotide with mutations within the RUNX1 rec-
ognition sequence was able to compete for binding of
His-PBF to P2, suggesting that PBF and RUNX1 do not
recognize the same DNA sequences. To map nucleo-
tides necessary for binding of PBF to P2 we used a set
of oligonucleotides encoding the P2 with different muta-
tions as probes in gel-shift experiments, which are sum-
marized in Fig. 3A. PBF recognizes the 3 half of the E2
binding site P2, since the oligonucleotide P2C, which still
interacts with RUNX1 like wildtype (Schmidt et al., 1997),
as well as the oligonucleotides P2D and P2F bound only
weakly. The oligonucleotide P2E bound PBF like wildtype
P2TATA, indicating that the T at the 3 end of the E2
binding site is not involved in PBF binding, which is also
confirmed by the use of P2E1. The 5 boundary of the PBF
binding site within P2 could be determined by using
oligonucleotide P2C1, which still binds (Fig. 3A). The
results were confirmed by using the various oligonucle-
otides as competitors (data not shown). In summary, the
gel shifts shown in Fig. 3A demonstrate that His-PBF
binds to the sequence CCGG within the E2 binding site
P2 (5ACCGCACCCGGT3, in boldface type).
To analyze whether PBF and RUNX1 are able to bind
simultaneously to the P2 element, we added the DNA
binding domain of RUNX1, , and His-NPBF together to
limiting amounts of labeled P2 TATA oligonucleotide.
Figure 3B shows that in the presence of both proteins a
new complex can be detected with a slightly slower
mobility than the His-NPBF–P2 TATA complex. In order
to confirm that this complex contains the  domain of
RUNX1 in addition to PBF, we used CBF , which is not
able to bind to DNA on its own, but forms a ternary
complex with DNA only in the presence of . The addi-
tion of  to PBF did not affect the migration of the PBF–P2
TATA complex, but in the presence of PBF and , a
supershift was created by , indicating that  is present
in the complex in addition to PBF (Fig. 3B). This demon-
strates that both proteins are able to bind together to the
FIG. 2—Continued
FIG. 2. (A) Nucleotide sequence of PBF and its predicted amino acid sequence. NPBF is encoded by the nucleotides 679–1868 while the open
reading frame of full-length PBF starts at nucleotide 338. The TFIIIA-like Zn-finger (at position 1175–1250) is marked by asterisks. (B) Western blot of
nuclear extracts from RTS3b (lane 4) as well as from RTS3b cells, transiently transfected with an expression vector for full-length PBF (lane 3).
Bacterially expressed, purified, His-tagged PBF (rPBF) has been included as a positive control in two different amounts (lanes 1, 2). The position of
PBF is indicated. The right panel shows indirect immunofluorescence of RTS3b cells or C33A cells transiently transfected with the empty vector (a)
or a eukaryotic expression vector for PBF (b) developed with the antiserum directed against bacterially expressed, purified His-PBF. A strong nuclear
fluorescence can be detected in transfected cells.
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FIG. 3. PBF recognizes the nucleotides CCGG in the HPV8 E2 binding site P2. (A) The binding of purified His-PBF to 250 pg of labeled
oligonucleotide containing the HPV8 E2 binding site P2 (P2TATA) was analyzed on its own (lane 2) or in the presence of a 250-fold excess of an
unrelated competitor oligonucleotide (n.s.), the homologue (P2TATA), or an oligonucleotide containing point mutations within the RUNX1 consensus
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P2 element of HPV8, which is in line with the finding
described before that the binding sites of both proteins
are not overlapping.
Since the recognition sequence of PBF contains the
CpG dinucleotide, which is a potential target for 5-cyti-
dine methylation, we wished to test whether methylation
would interfere with the binding of PBF. A P2 TATA oli-
gonucleotide which contains 5-methylcytidine of the CpG
dinucleotides on both strands within the putative PBF
binding site does not bind PBF (Fig. 3C).
PBF also binds to BS-1 in BPV1 and competes with
E2 for DNA binding
As already mentioned, the sequence of the BPV 1
E2BS-1 is conserved to the P2 of HPV8. A sequence
alignment of the two E2 binding sites is given in Fig. 4A.
To test whether BS-1 is bound by PBF we used oligonu-
cleotides encoding either the wildtype BPV1 E2BS-1 or
mutated versions (BPV1 BS-1 mt1, BPV1 BS-1 mt2) that
are defective in RUNX1 binding (Schmidt et al., 1997) as
competitors in gel-shift assays. All three oligonucleo-
tides were efficient competitors for PBF binding to P2
TATA (Fig. 4A), suggesting that PBF also recognizes the
BPV1 E2BS-1. The mutations present in the oligonucleo-
tides BPV1 BS-1mt3 and mt4 abolished binding of PBF
(Fig. 4A), which confirms that PBF also recognizes the 3
half of this E2 binding site. To enlighten the involvement
of PBF in P7185 activity, the point mutations present in the
oligonucleotides BPV1 E2BS-1 mt3 and mt4 were intro-
duced into a reporter construct containing the luciferase
gene under control of the BPV1 P7185 promoter including
BS-1 (Schmidt et al., 1997). In RTS3b cells, promoter
FIG. 3—Continued
sequence (P2 mut PEBP2). To map the nucleotides necessary for PBF binding, the various oligonucleotides containing different mutations as
indicated in the figure have been used as labeled probes and were incubated either with () or without () His-PBF. The sequences of the
oligonucleotides used in these experiments are summarized at the top. (B) PBF and the DNA binding domain of RUNX1  bind to P2 simultaneously.
Labeled P2 TATA oligonucleotide has been incubated with bacterially expressed, purified His-N PBF (lane 5) or with the DNA binding domain of
RUNX1  (lane 3) alone or with both proteins together (lane 7). The bacterially expressed, purified CBF does not bind to DNA on its own (lane 2),
but creates a supershift in the presence of RUNX1  (lane 4) bound to P2 TATA. CBF does not affect the binding of PBF on its own (lane 6); however,
in the presence of PBF and RUNX1 , a new supershifted complex is produced by CBF (lane 8). For better resolution, the PBF-containing complexes
have been scaled up, which is shown on the right. The positions of the protein–DNA complexes are indicated. (C) Binding of His-NPBF to an
oligonucleotide containing the HPV8 P2 either nonmethylated (non-me.) or methylated (me.) as indicated above.
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activity was decreased by 70 and 55% due to mt3 and
mt4, respectively. In C33A cells, the mutation resulting in
loss of PBF binding in vitro reduced promoter activity by
30 and 20%, respectively (Fig. 4B). In summary, these
experiments demonstrate that PBF binds to the E2BS-1
of BPV1 and is required for full activity of the P7185.
Binding of E2 to HPV8 P2 and BPV1 BS-1 leads to
repression of HPV8 P7535 and BPV1 P7185, respectively
(Stenlund and Botchan, 1990; Vande Pol and Howley,
1990; Stubenrauch and Pfister, 1994; Stubenrauch et al.,
1996). This repression is supposed to be mediated by
competition for DNA binding between E2 and positively
acting cellular factors. Previously, we could demonstrate
that the DNA binding domain of RUNX1, which binds to
FIG. 4. (A) PBF binds to BPV1 E2 BS-1. His-NPBF was incubated with 250 pg of an oligonucleotide encoding the HPV8 P2 (P2 TATA), either alone
(lanes 2) or in the presence of a 250-fold excess of competitors as indicated (lanes 3–7). On the right, the binding of bacterially expressed His-PBF
to labeled BPV1 E2 BS-1 wt, BPV1 E2BS-1 mt3, and BPV1 E2BS-1 mt4 oligonucleotides has been analyzed (lanes 11–13). The labeled probes in the
absence of any protein are shown in lanes 1 and 8–10. The sequences of the oligonucleotides used in this experiment are summarized above. At
the top an alignment of the sequences surrounding HPV8 P2 and BPV1 BS-1 is shown. The RUNX1 binding site and the PBF recognition motif are
boxed, and the E2 palindromic sequences are in boldface type. (B) Mutations within the E2BS-1, which abolish the binding of PBF in vitro, reduce P7185
promoter activity. Luciferase reporter constructs with part of the BPV1 LCR from position 7145 to 7276 including the P7185 and the wildtype E2BS-1
(BPV1 P7185-Luc) or two mutated versions of E2BS-1 (BPV1 P7185mt3-Luc and BPV1 P7185mt4-Luc) as indicated above have been transiently transfected
into RTS3b cells or C33A cells. The RLUs have been normalized by the -gal activity, an expression vector for which has been cotransfected, to
determine the relative activities. That of the construct containing the wildtype E2BS-1 was set as 100% and percentage relative activities of the mutant
versions have been calculated. The error bars represent the standard deviation of 10 experiments. (C) PBF and BPV1 E2 do not bind to BPV1 E2BS-1
simultaneously. 50 pg of an oligonucleotide encoding the BPV1 E2BS-1 was incubated with increasing amounts of purified BPV1 E2 protein alone
(lanes 2–5) or together with a constant amount of His-NPBF (lanes 7–10). The binding of His-NPBF on its own is shown in lane 6.
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the 5 half of these two E2 binding sites, and E2 compete
for DNA binding (Schmidt et al., 1997). To investigate
whether the binding of PBF and the binding of E2 to BS-1
are mutually exclusive we used BPV1 E2, expressed and
purified from bacteria with six histidines at its N-ter-
minus. The gel shift shown in Fig. 4C confirms that
increasing amounts of E2 displace His-NPBF bound to
BS-1, demonstrating that E2 and PBF compete for DNA
binding.
Endogenous PBF binds to E2 binding sites BPV1 BS-1
and HPV8 P2
In order to analyze whether endogenous PBF will bind
to the two E2 binding sites, we performed gel-shift as-
says with nuclear extracts. When incubating labeled P2
TATA oligonucleotide with nuclear extracts from RTS3b,
two complexes (A and B) were observed (Fig. 5A). The
faster migrating complex A could not be competed effi-
ciently by any of the competitors, indicating that the
responsible factor might be of low specificity. The slower
migrating complex B was efficiently competed by an
excess of unlabeled P2TATA and BPV1 E2BS-1 oligonu-
cleotides, respectively. The complexes A and B can also
be detected when C33A nuclear extracts were used,
although the intensity of complex B appears weaker than
in RTS3b cells. The P2 TATA derived oligonucleotides
P2C and P2D, containing mutations abolishing the bind-
ing of His-PBF (see Fig. 3A), failed to compete for bind-
ing, whereas the oligonucleotide P2E, which still binds
His-PBF (see Fig. 3A), was an efficient competitor (Fig.
5A). The complexes A and B can also be detected when
BPV1-E2BS1 was used as probe. Again, mutations abol-
ishing binding of recombinant PBF to BS-1 also abolish
the ability to compete for complex B (BPV1 BS-1mt3 and
BPV1 BS-1 mt4) (data not shown). Taken together, gel-
shift experiments with nuclear extracts demonstrate that
a cellular factor with sequence specificity similar to that
of His-PBF binds to HPV8 P2 and to BPV1 E2BS-1. To
further characterize this cellular factor present in com-
plex B, we performed supershift experiments with the
anti-His-PBF antiserum. Complex B was not affected by
the preimmune serum. The addition of the immune se-
rum to the binding reaction did not result in a supershift,
but led to disappearance of this complex, indicating that
PBF bound by antibodies is unable to bind to P2 TATA.
This could be observed with nuclear extracts from RTS3b
(Fig. 5B) and C33A cells (data not shown), respectively.
The specificity of the reaction is confirmed by adding the
antiserum to an unrelated protein bound to P2 TATA,
which was the DNA binding domain of RUNX1, . The
higher migrating complex, which was detectable in the
presence of both the preimmune and the immune sera
(indicated by an arrow in Fig. 5B), was also present after
incubation with RUNX1  and P2TATA and thus is not
related to PBF. When performing similar gel shifts with
nuclear extracts from RTS3b cells, which have transiently
been transfected with a eukaryotic expression vector for
PBF, the intensity of complex A was unchanged, whereas
that of complex B was stronger compared to nontrans-
fected cells. Again, complex B disappeared completely,
FIG. 5. (A) Cellular factors binding to P2 TATA and BPV1 E2 BS-1.
Nuclear extracts prepared from RTS3b (lanes 2–8) or C33A cells (lanes
9–11) have been incubated with labeled oligonucleotides encoding the
P2 TATA. A 250-fold excess of unlabeled competitor oligonucleotides
(comp.) was added as indicated. The sequences of the oligonucleo-
tides used in this experiment are given in Figs. 3A and 4A. P105 TATA
was used as unrelated competitor. The positions of the two complexes,
called A and B, are indicated. (B) Antibodies directed against bacterially
expressed, purified His-PBF specifically react with a cellular protein
binding to HPV8 P2 and BPV1 E2 BS-1. Nuclear extracts prepared from
RTS3b cells (lanes 4–6) or from RTS3b cells, which have been tran-
siently transfected with an expression vector for recombinant PBF
(RTS3b/PBF NE), have been incubated with labeled P2TATA oligonu-
cleotide alone or in the presence of the preimmune serum (PI) or a
polyclonal immune serum (I) directed against bacterially expressed
PBF. As a negative control, the preimmune and immune sera were
incubated with the DNA binding domain of RUNX1  and P2TATA. A
new complex, which appears in the presence of the preimmune or the
immune serum, respectively, is indicated by an arrow.
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when the immune serum was added to the binding
reaction (Fig. 5B). This further supports the notion that
PBF binds to P2 TATA in vivo.
Cellular factors binding to BPV1 E2 binding site 1 are
activators of transcription
In order to test whether PBF will be an activator we
examined the effect of multimerizing the PBF binding
sites in front of a minimal promoter. We cloned either one
or three copies of the BPV1 E2BS-1 in front of the minimal
adenovirus major late promoter (MLP) and transiently
transfected these constructs into C33A and RTS3b cells,
respectively. The activity of the promoter was stimulated
4-fold by one copy of the wildtype (wt) E2BS-1, whereas
three copies enhanced promoter activity by 38-fold, indi-
cating synergism between several binding sites in RTS3b
cells, which is typical for activators (Fig. 6). This activa-
tion was lost when either a mutation abolishing the
binding of RUNX1 in vitro (mt1) (Schmidt et al., 1997) or a
mutation abolishing PBF binding in vitro (mt3) (Fig. 4A)
was introduced. In C33A cells, which contain very low
levels of endogenous RUNX1 compared to RTS3b cells
(Schmidt et al., 1997), a 2-fold activation induced by one
site was not enhanced in the presence of three sites (Fig.
6). This experiment suggests that the binding of both
factors is required for efficient activation. Neither RUNX1
nor PBF is able to activate on its own.
DISCUSSION
Repression of HPV gene expression by the full-length
E2 protein usually occurs when E2 binding sites overlap
with the binding sites of cellular factors necessary for
basal promoter activity. Thus, isolating factors binding to
repression-mediating E2 binding sites might be a tool to
identify host cell transcription factors involved in PV gene
expression. The yeast one-hybrid system we used to
systematically screen for cellular proteins binding to the
HPV8 E2 binding site P2 allowed the identification and
subsequent cloning of full-length PBF. cDNAs identical to
parts of the PBF sequence have been found in a variety
of human tissues, such as testis and lung carcinoma,
and human cell lines, such as HeLa cells, indicating that
PBF is widely expressed. Endogenous PBF and rPBF
reveal nuclear localization, as expected for transcription
factors. We could confirm specific DNA binding of bac-
terially expressed, purified PBF by the use of oligonucle-
otides as probes or competitors in gel shifts (Figs. 3A
and 4A). rPBF binds the sequence CCGG within P2;
however, exhaustive mutagenesis would be required to
determine its consensus sequence and the contribution
of nucleotides flanking this motif.
With the use of antibodies generated against bacteri-
ally expressed, purified His-PBF we could show that this
antibody reacts with a cellular protein(s) binding to the
BPV1 E2BS-1 and HPV8 P2, respectively. Pretreatment of
nuclear extracts from RTS3b cells with anti-rPBF antibod-
ies specifically interfered with binding to the two repres-
sion-mediating E2 binding sites. The antibody competes
for DNA binding, rather than producing a supershifted
complex. This may be due to the fact that the antibody
was raised against the entire rPBF, including the DNA
binding domain. The observation that in nuclear extracts
from RTS3b cells, which have been transiently trans-
fected with an expression vector for rPBF, more complex
B is present than in nontransfected cells also supports
the notion that the factor produced from the gene that we
cloned might be identical to the cellular protein binding
to P2 and E2BS-1. In these gel shifts, we could not detect
a complex corresponding to RUNX1 bound to P2 or BS1,
respectively. However, RUNX1 binds here, since the
binding of RUNX1 to the high-affinity site PEA2 of the
polyoma virus enhancer can be competed by an excess
of the oligonucleotides, respectively (Schmidt et al., 1997;
and data not shown). It is possible that the amount of
endogenous RUNX1 present in RTS3b cells is not suffi-
cient to obtain a detectable complex in gel-shift assays
due to the reduced affinity of RUNX1 for HPV8 P2 and
BPV1 E2BS-1 (Schmidt et al., 1997).
Our data indicate that the binding of PBF is necessary
for full activity of HPV8 P7535 and BPV1 P7185. The role of
PBF in regulation of PV gene expression was monitored
by introducing point mutations that abolish binding of
PBF in vitro into appropriate reporter constructs. We
FIG. 6. Cellular factors binding to BPV1 E2 BS-1 are activators of
transcription in RTS3b cells. A luciferase reporter construct containing
the minimal adenovirus major late promoter (Ad. MLP) behind either
one (1) or three copies (3) of wildtype BPV1 E2 BS-1 (wt), of BPV1
E2 BS-1 with a point mutation within the RUNX1 consensus motif (mt1;
the sequence is shown in Fig. 4A), of BPV1 E2 BS-1 with a point
mutation, abolishing PBF binding in vitro (mt3, sequence is shown also
in Fig. 4A), or of BPV1 E2 BS-1 containing both mutations (mt1/3) was
transiently transfected either in RTS3b cells or in C33A cells. The
activity of the MLP present in the construct without any E2 binding site
has been set as 1. The fold activity due to the presence of any BPV1 E2
BS-1 represents the means of four experiments and the error bars are
given. The structure of the reporter constructs is shown above the
graph.
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cannot exclude the possibility that the decrease of pro-
moter activity due to point mutations might result from
loss of the binding of another cellular transcription factor.
For example, the binding of the general transcription
factor TFIIB might be affected since our point mutations
that abolish PBF binding are very close to the TATA box
of P7535. Sequences located immediately upstream of the
TATA element have been shown to affect the ability of the
general transcription factor TFIIB to enter the transcrip-
tion complex. Obviously nucleotides up to the seventh
base upstream of the TATA box can be contacted by
TFIIB. Efficient binding of TFIIB correlated with increased
basal transcription in vitro (Lagrange et al., 1998). The
mutations within the HPV8 P2 lie within this region.
However, the exchange of the two nucleotides located
immediately upstream of the TATA box should affect P7535
activity more strongly (Fig. 1, construct pP2E-Luc) than
the nucleotides further upstream mutated in P2D and
P2C (Lagrange et al., 1998) if weakening of the TFIIB
interaction will be the reason for reduced promoter ac-
tivity. Thus, the reduced promoter activity due to the
mutations P2C and P2D (Fig. 1) may rather result from
loss of PBF binding. The mutations in BPV1 are located
downstream of the TATA box (Fig. 4B). TFIIB binding
should therefore not be altered in these cases.
In the case of BPV1, the loss of PBF binding causes a
greater reduction of P7185 activity in RTS3b cells than in
C33A cells (Fig. 4B). A difference is also obvious with the
synthetic reporter constructs. Whereas RTS3b cells re-
veal a high level of synergy between three E2BS-1 in
activation of the MLP, this is not detectable in C33A cells
(Fig. 6). This may be due to smaller amounts of endog-
enous PBF present in C33A cells (see Fig. 5A). In addi-
tion, we have already previously observed a difference in
regulation of BPV1 P7185 activity between these two cell
lines. A mutation within BPV1 E2BS-1, which abolished
the binding of RUNX1, only marginally reduced P7185 ac-
tivity in C33A cells, whereas P7185 activity dropped by
about 50% in RTS3b cells. We could correlate this with
only very small amounts of endogenous RUNX1 in C33A
cells (Meyers et al., 1995; Schmidt et al., 1997). The
reduced effect of mutations abolishing PBF binding to
BPV1 E2BS-1 in C33A cells might also be explained by
PBF depending on cooperation with RUNX1. Thus, the
stronger reduction of BPV1 P7185 activity due to the mu-
tation of the PBF element in RTS3b cells (see Fig. 4B)
might be related to higher levels of RUNX1 present in
RTS3b cells (Schmidt et al., 1997). In contrast to BPV1
E2BS-1, the abrogation of PBF binding to P2 of HPV8 on
P7535 activity is rather similar in the skin carcinoma cell
line RTS3b and in C33A (Fig. 1). Here, the small amounts
of RUNX1 could be sufficient for necessary cooperation
since HPV8 P2 showed a higher affinity to RUNX1 than
BPV1 E2BS-1 (Schmidt et al., 1997). Our model that the
two factors cooperate is supported by data obtained with
the synthetic reporter constructs containing multimerized
E2BS-1 (Fig. 6). The loss of activation due to mutations
within the RUNX1 motif indicates that PBF on its own
may not be able to activate but requires RUNX1. On the
other hand, mutation of the PBF recognition sequence
also eliminates activation, demonstrating that RUNX1
also must cooperate with PBF for activation. The inability
of RUNX1 to activate from multimerized binding sites has
been observed previously (Bruhn et al., 1997). RUNX1 is
known to regulate transcription in cooperation with cel-
lular DNA binding transcription factors, like Ets-1, c-Myb,
C/EBP, MITF, and Smads (Zaiman et al., 1998; reviewed
in Ito, 1999). Thus, PBF may be another cooperation
partner for RUNX1. Slight differences in the effects of
RUNX1/PBF double mutations observed with HPV8 P7535-
Luc in RTS3b cells (Fig. 1) may point to further possible
cooperation partners.
We have identified PBF by binding to a repression-
mediating E2 recognition site. The complete overlap of
the two sites already implies that binding of E2 and that
of PBF are mutually exclusive, which has been confirmed
experimentally (Fig. 4C). In view of the extensive se-
quence homology between PBF and E2 recognition se-
quences there is a high probability that both sites colo-
calize. BPV1, for example, contains 17 E2 binding sites; 5
of them include putative PBF binding sites, namely, BS-1,
BS-3, BS-9, BS-11, and BS-17. Most of these sites do not
mediate repression by E2. For example, BS-9 plays an
essential role within the E2 responsive enhancer I, re-
sponsible for activation of the promoters in position 7940
and 89 (Spalholz et al., 1987). Since PBF binding may
also be affected by sequences flanking the CCGG motif,
PBF may not bind to these sites at all. Moreover, dis-
placement of PBF by E2 may not lead to repression,
because PBF plays only a minor role as activator in these
cases due to the lack of nearby cooperating factors.
Thus, the context dependence of PBF may allow tran-
scription to be regulated very specifically.
Another factor related to PBF is the mouse GLUT 4
(adipose-/muscle-specific glucose transporter 4) en-
hancer factor. This protein, which shows 35% similarity to
PBF, binds to the GGCC element within the GLUT4 pro-
moter and cooperates with MEF2 (myocyte enhancer
factor 2) in GLUT4 transcriptional activity (Oshel et al.,
2000). Thus, both factors seem to be similar in binding to
G/C-rich sequences and in cooperating with another
transcription factor to regulate transcription.
MATERIALS AND METHODS
Plasmid constructions
The plasmid p7535-Luc contains the 5 part of the NCR
of HPV8(7077-7628) in front of the luciferase gene and
has been described previously (Stubenrauch et al., 1996).
P2C-Luc was obtained by inserting the HPV8-specific
BamHI–Eco47III fragment isolated from P2C-Cat into the
luciferase reporter plasmid pALuc (Dong et al., 1994) and
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was kindly provided by F. Stubenrauch. The plasmids
pP2D-Luc and pP2E-Luc were created by site-directed
mutagenesis according to the PCR protocol (Ausubel et
al., 1992). The construct BPV1 p7185-Luc, which was
described previously (Schmidt et al., 1997), was used as
template for in vitro mutagenesis with the Chameleon Kit
(Stratagene) to create BPV1 p7185mt3-Luc and BPV1
p7185mt4-Luc. The reporter constructs used in the yeast
one-hybrid assay were obtained by inserting four or five
copies of the double-stranded oligonucleotides encod-
ing the P2 of HPV8 (5AATTCACCGACCGCACCCGGTA-
CAT3; producing EcoRI compatible ends) into the EcoRI
site of pHISi-1 and pLacZi (Clontech), respectively. To
allow the expression of PBF with a tag of six histidines at
its N-terminus the ORF was amplified by PCR from the
pACT-PBF isolated by the yeast one-hybrid system with a
primer complementary to the 5 end of the ORF followed
by an XhoI site and the primer pACT 3 (Clontech). The
PCR product was cloned into the same site of pET14B
(Novagene). To reconstitute the entire ORF for PBF, a
PCR product amplified from the pUC-5RACE plasmid
containing the 5 end was ligated into pET14B N-PBF
cut with BstXI and XhoI. To create the expression vector
PBF/pCEP-4, pET14B-PBF was digested with XhoI and
BamHI and the isolated insert ligated into the same sites
of pCEP4 (Invitrogen). All constructs have been verified
by sequencing.
The yeast one-hybrid screen
Yeast cell maintenance and the one-hybrid screen
were performed according to the MATCHMAKER one-
hybrid system protocol by Clontech. In brief, to integrate
the reporter plasmids into the yeast genome of the strain
YM4271, the plasmids were linearized within the selec-
tion marker gene before transformation. This resulting
yeast strain was transformed with an expression library
encoding cDNAs isolated from the human keratinocyte
cell line HaCat fused to the Gal4 activation domain (pur-
chased from Clontech). Transformed cells were selected
in minimal SD medium lacking uracil, histidine, and
leucine, in the presence of 75 mM 3-AT (Sigma), to
suppress growth conferred by basal expression of the
HIS3 gene. Colonies were rescreened for expression of
-galactosidase using X-gal and ONPG as substrate,
respectively.
Isolation of full-length PBF
The sequence of N-PBF was used to create a set of
nested gene-specific primers (GSP1, 5GGCACTTGTACAT-
CACCTTCACAG3; GSP2, 5CGTGGAGCTGGTTCGTCCAG-
C3; and GSP3, 5ACATGCATGCGGGTCAGGATCGGTCTC-
AAAGCCATGATC3, contains a Sph1 site) to identify the 5
end of PBF by specific 5 rapid amplification of cDNA ends
(5RACE System, Gibco BRL). RT-PCR was performed with
cytoplasmic RNA isolated from HaCat. The resulting
5RACE–PCR product was cleaved with SalI–SphI and in-
serted into the same sites of pUC18 for amplification and
sequencing.
Cell culture and transfections
C33A cells were grown in Dulbecco’s modified Eagle’s
medium with Glutamax, supplemented with 7.5% fetal
calf serum and the antibiotics penicillin and streptomy-
cin. RTS3b cells were cultivated in E medium (Meyers et
al., 1994). Transient transfection assays in RTS3b cells
were performed with FuGENE transfection reagent
(Roche Diagnostics). For transfection 1  105 cells per
well were plated into 6-well plates. C33A cells were
transfected by the CaCl2 method as described previously
(Ham et al., 1994). Twenty to 24 h later, transfections
were carried out with the amount of luciferase reporter
plasmid indicated in the figure legends and 0.5 g of a
plasmid encoding the -galactosidase gene under the
control of Rous sarcoma virus LTR. Forty to 48 h later
cells were harvested.
Luciferase and -galactosidase assays
Total cellular extracts were prepared as described
previously as were luciferase and -galactosidase as-
says (Ham et al., 1994; Steger and Corbach, 1997). To
account for variations in transfection efficiencies, pro-
moter activities were expressed as luciferase/-galacto-
sidase activity ratios.
Expression and purification of proteins, preparation of
nuclear extracts, and gel retardation assays
The induction of the expression of His-tagged PBF and
its purification were performed as described previously
(Steger and Corbach, 1997). Nuclear extracts were pre-
pared according to the protocol of Schreiber et al. (1989).
Purified proteins as well as nuclear extracts were incu-
bated with 1 g poly(dI–dC), 0.5 g single-stranded
salmon sperm DNA, and 65 ng of competitor (unless
stated otherwise) in the presence of 0.5 g/l BSA; 12
mM HEPES, pH 7.9; 10% glycerol; 0.5 mM EDTA; 4 mM
MgCl2; 60 mM KCl; 0.1% NP-40; and 4 mM spermidine for
15 min at room temperature before 250 pg of 32P-labeled
double-stranded oligonucleotides was added, followed
by another 15-min incubation. Protein–DNA complexes
were resolved in a 0.5 Tris–borate–EDTA–4.5% nonde-
naturing polyacrylamide gel at 160 V for 1.5 h at room
temperature. The gel was dried at 80°C for 2 h and
autoradiographed.
Generation of anti-PBF antibodies
Rabbits were immunized with bacterially expressed
purified His-PBF according to the protocol of Pineda
(Berlin).
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Immunofluorescence tests
Cells were transfected with 100 ng expression plasmid
and 100 ng carrier DNA as described above. After 48 h
cells were washed with PBS, fixed in 2% formaldehyde
for 10 min, washed twice, and blocked for 20 min in
PBS/10% FCS. After a 1-h incubation with the PBF-spe-
cific antiserum (diluted 1:200 in PBS; 10% FCS supple-
mented with 0.1% saponine) and three washing steps
with PBS/10% FCS, a 1:50 dilution of a goat anti-rabbit
FITC (Jackson ImmunoResearch) was applied. The cells
were washed again and kept in PBS for microscoping.
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